Germline mutations in CHEK2 have been primarily associated with predisposition to breast, prostate and colorectal cancers but there is increasing evidence for an association with RCC with an approximately two-fold increased lifetime risk [35]. This evidence concerns the gene CHEK2 and renal cell carcinoma.